Acrivon Therapeutics(US:ACRV) Globenewswire·2026-03-19 11:21Core Insights - Acrivon Therapeutics reported a confirmed overall response rate (cORR) of 52% for ACR-368 in serous endometrial cancer (EC), a subtype responsible for approximately 50% of EC mortality [1][3] - The company is expanding its clinical trials for ACR-368 by initiating Arm 3 and Arm 4 to explore its efficacy in serous EC patients [1][2] - Acrivon has a strong financial position with $118.6 million in cash and equivalents as of December 31, 2025, expected to fund operations into Q2 2027 [1][13] ACR-368 Development - ACR-368 is a CHK1/CHK2 inhibitor currently in a registrational-intent Phase 2b trial, with promising data presented at the ESGO Congress [3][15] - The trial includes an interim analysis showing a cORR of 52% in serous EC subjects, compared to 22% in non-serous EC subjects [3][4] - A fourth cohort (Arm 4) will investigate ACR-368 monotherapy in biomarker-unselected serous EC subjects, similar to Arm 3 [3][4] ACR-2316 and ACR-6840 - Initial data from the Phase 1 trial of ACR-2316, a WEE1/PKMYT1 inhibitor, showed favorable tolerability and clinical activity in small cell lung cancer and squamous non-small cell lung cancer [5][16] - ACR-6840, an oral CDK11 inhibitor, has been nominated as a development candidate from the company's AP3-driven cell cycle program [6][16] Financial Performance - The net loss for Q4 2025 was $19.0 million, compared to $22.8 million in Q4 2024, while the full-year net loss was $77.9 million, down from $80.6 million in 2024 [9][20] - Research and development expenses decreased to $14.7 million for Q4 2025 from $18.6 million in Q4 2024, reflecting a focus on endometrial cancer trials [11][20] Upcoming Milestones - The company anticipates achieving CTA approval in the EU for Arm 3 by Q1 2026 and plans to initiate enrollment for Arm 4 in the first half of 2026 [10] - Additional clinical data for ACR-2316 is expected in 2026, along with an IND filing for ACR-6840 [10][16]